Soluble antagonists to BMP signaling were also unremarkable in comparison to lytic‐ or blastic‐like tumor induced bone disease phenotype prostate cancer cell lines, with only TWSG1 having slight elevation in lytic‐like cells (Figure 2B). The gene discussed is TWSG1; the disease is prostate carcinoma.